Birchview Capital, LP Halozyme Therapeutics, Inc. Transaction History
Birchview Capital, LP
- $95 Million
- Q2 2025
A detailed history of Birchview Capital, LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 10,000 shares of HALO stock, worth $664,700. This represents 0.55% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$664,700
Previous $638,000
18.5%
% of portfolio
0.55%
Previous 0.57%
Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
623Shares Held
127MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.17 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$814 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$395 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$230 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$226 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.26B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...